CALGB Web Site

calgb.org > CALGB Web Site Home

Welcome to the Cancer and Leukemia Group B Web Site

The Cancer and Leukemia Group B (CALGB) is a national clinical research group sponsored by the National Cancer Institute, with its Central Office headquartered at the University of Chicago and its Statistical Center located at Duke University. The CALGB was founded in 1956 with a goal of bringing together clinical oncologists and laboratory investigators to develop better treatments for cancer. Since 1956, CALGB has grown into a national network of 26 university medical centers, over 225 community hospitals and more than 3000 oncology specialists who collaborate in clinical research studies aimed at reducing the morbidity and mortality from cancer, relating the biological characteristics of cancer to clinical outcomes and developing new strategies for the early detection and prevention of cancer. [continued]

CALGB News

Spring 2008 Issue of CAL-GAB Newsletter Now Available

April 15, 2008, 02:39:04 pm in Broadcasts.

Full Text

Winter 2007 Issue of CAL-GAB Newsletter Now Available

December 18, 2007, 12:02:14 pm in Publications.

Full Text

2007 CALGB Central Office and Statistical Center Registration/Randomization and Specimen Repositories Holiday Schedules

November 14, 2007, 02:36:15 pm in Broadcasts.

Full Text

Fall 2007 Issue of the CAL-GAB Newsletter Now Available

October 18, 2007, 11:11:45 am in Broadcasts.

Full Text

Summer 2007 issue of the CALGaB newsletter is now available

August 16, 2007, 03:31:38 pm in Broadcasts.

Full Text

Next >>>

CALGB Foundation

The Cancer and Leukemia Group B Foundation is a nonprofit, tax-exempt foundation formed for the primary purpose of aiding the Cancer and Leukemia Group B national clinical trials cooperative group. The CALGB Foundation supports the clinical trials and laboratory research of the CALGB, as well as efforts to educate the medical community on methods of cancer diagnosis, treatment, and prevention. Recent initiatives supported by the CALGB Foundation:

New chemotherapy treatments for breast, prostate, lung and colorectal cancer.
New surgical techniques for breast and colon cancer.
Genetic studies of breast cancer risk.
Molecular determinants of response to therapy for breast, colorectal and lung cancer as well as leukemia.
Improving the quality of life of cancer patients and their caregivers.